The aim of this study was to evaluate the usefulness of bone formation serum markers bone alkaline phosphatase (bALP) and osteoprotegerin (OPG), and bone resorption serum markers tartrate-resistant acid phosphatase isoform-5b (TRACP 5b), carboxy terminal cross-linked telopeptide of type I collagen (CTX), and receptor activator of nuclear factor-κ ligand (RANKL) in patients with NSCLC and bone metastases. Twenty-six patients with advanced NSCLC (21 men, 5 women, median age 74 years, range 57-79 years) scheduled for palliative chemotherapy were enrolled in the study. All patients underwent whole body (18)F-FDG PET/CT that showed the presence of bone metastases in 12 (cases). Controls (N=14) were patients with negative (18)F-FDG PET. TRAC5b (OR=0.09, 95%CI 0.01-0.56, p=0.016), RANKL (OR=0.13, 95%CI 0.02-0.78, p=0.044), and OPG (OR=0.13, 95%CI 0.02-0.76, p=0.047) exhibited a good sensitivity, whilst CTX (OR=0.20, 95%CI 0.04-1.06, p=0.11) and bALP (0.54, 95%CI 0.11-2.55, p=0.69) were not sensitive enough in cases vs. controls. In conclusions, in patients with NSCLC and bone metastases the measurement of serum TRAC55, RANKL, and OPG could be useful in diagnosing advanced disease early.
Serum markers of bone remodeling in patients with advanced non-small cell lung cancer and bone metastases.
LUMACHI, FRANCO;
2014
Abstract
The aim of this study was to evaluate the usefulness of bone formation serum markers bone alkaline phosphatase (bALP) and osteoprotegerin (OPG), and bone resorption serum markers tartrate-resistant acid phosphatase isoform-5b (TRACP 5b), carboxy terminal cross-linked telopeptide of type I collagen (CTX), and receptor activator of nuclear factor-κ ligand (RANKL) in patients with NSCLC and bone metastases. Twenty-six patients with advanced NSCLC (21 men, 5 women, median age 74 years, range 57-79 years) scheduled for palliative chemotherapy were enrolled in the study. All patients underwent whole body (18)F-FDG PET/CT that showed the presence of bone metastases in 12 (cases). Controls (N=14) were patients with negative (18)F-FDG PET. TRAC5b (OR=0.09, 95%CI 0.01-0.56, p=0.016), RANKL (OR=0.13, 95%CI 0.02-0.78, p=0.044), and OPG (OR=0.13, 95%CI 0.02-0.76, p=0.047) exhibited a good sensitivity, whilst CTX (OR=0.20, 95%CI 0.04-1.06, p=0.11) and bALP (0.54, 95%CI 0.11-2.55, p=0.69) were not sensitive enough in cases vs. controls. In conclusions, in patients with NSCLC and bone metastases the measurement of serum TRAC55, RANKL, and OPG could be useful in diagnosing advanced disease early.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
